Evaxion A/S (NASDAQ:EVAX)
| Market Cap | 21.03M-53.0% |
| Revenue (ttm) | 7.49M+135.9% |
| Net Income | -8.65M+27.7% |
| EPS | -6.20+36.8% |
| Shares Out | 6.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 465,685 |
| Open | 3.11 |
| Previous Close | 2.83 |
| Day's Range | 2.97 - 3.60 |
| 52-Week Range | 2.72 - 8.10 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 11.67(+250.45%) |
| Earnings Date | Nov 19, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About EVAX
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
$EVAX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EVAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EVAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EVAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EVAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EVAX from public contracts
Source: USAspending.gov
EVAX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EVAX’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.